The efficacy and safety of PDE5 inhibitors

Clinical Cornerstone

Volumn 7, Issue 1, 2005, Pages 47-55

  Rashid, Aly ^a  

^a Leicester Hospitals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CYCLIC GMP; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; KETOCONAZOLE; NIFEDIPINE; NITRIC ACID DERIVATIVE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE V INHIBITOR; PROCAINAMIDE; PROTEINASE INHIBITOR; QUINIDINE; RIFAMPICIN; SAQUINAVIR; SILDENAFIL; SOTALOL; TADALAFIL; UNINDEXED DRUG; VARDENAFIL; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FACE DISORDER; FLU LIKE SYNDROME; FLUSHING; FOOD DRUG INTERACTION; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIMB PAIN; LIVER DYSFUNCTION; MYALGIA; NAUSEA; NOSE CONGESTION; PENIS DISEASE; PENIS ERECTION; POPULATION RESEARCH; PRIAPISM; PROSTATE CANCER; QT PROLONGATION; RHINITIS; RISK ASSESSMENT; SCORING SYSTEM; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SINUSITIS; SMOOTH MUSCLE RELAXATION; STOMACH DISEASE; URINARY TRACT INFECTION; VISUAL DISORDER; DRUG EFFECT; IMPOTENCE; MALE; REVIEW; SAFETY; TREATMENT OUTCOME;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SAFETY; TREATMENT OUTCOME;

EID: 27744508710     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(05)80048-1     Document Type: Article

References (30)

1. Wespes E Amar E Hatzichristou D Montorsi F Pryor J Vardi Y Guidelines on erectile dysfunction Eur Urol 41 2002 1-5
2. Lue TF Erectile dysfunction N Engl J Med 342 2000 1802-1813
3. Padma-Nathan H Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction Am J Cardiol 92 2003 19M-25M
4. Viagra® (sildenafil citrate) prescribing information 2004 Pfizer Inc New York (NY)
5. Cialis® (tadalafil) prescribing information 2004 Eli Lilly and Co. Indianapolis (IN)
6. Gresser U Gleiter CH Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature Eur J Med Res 7 2002 435-446
7. Levitra® (vardenafil HCI) prescribing information 2004 Bayer Pharmaceuticals Corporation West Haven (CT)
8. Carson CC Burnett AL Levine LE Nehra A The efficacy of sildenafil citrate (Viagra) in clinical populations: An update Urology 60 2 Suppl 2 2002 12-27
9. Goldstein I Lue TF Padma-Nathan H Rosen RC Steers WD Wicker PA Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group New Engl J Med 338 1998 1397-1404
10. Fink HA Mac Donald R Rutks IR Nelson DB Wilt TJ Sildenafil for male erectile dysfunction: A systematic review and meta-analysis Arch Intern Med 162 2002 1349-1360
11. Carson CC Rajfer J Eardley I Carrier S Denne JS Walker DJ et al. The efficacy and safety of tadalafil: An update BJU Int 93 2004 1276-1281
12. Brock GB McMahon CG Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses J Urol 168 2002 1332-1336
13. Porst H Padma-Nathan H Giuliano F Anglin G Varanese L Rosen R Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial Urology 62 2003 121-125 discussion 125-6
14. Hellstrom WJ Gittelman M Karlin G et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, double-blind, 26-week placebo-controlled pivotal trial Urology 61 4 Suppl 1 2003 8-14
15. Sussman DO Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors J Am Osteopath Assoc 104 3 Suppl 4 2004 S11-S15
16. Rajagopalan P Mazzu A Xia C Dawkins R Sundaresan P Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction J Clin Pharmacol 43 2003 260-267
17. Bella AJ Brock GB Tadalafil in the treatment of erectile dysfunction Curr Urol Rep 4 2003 472-478
18. Padma-Nathan H Kaufman J Taylor T Earliest time of onset of erection with vardenafil in an at-home setting 2003 American Urological Association annual meeting Chicago (IL)
19. Arnold LM Vardenafil and tadalafil: Options for erectile dysfunction Current Psychiatry Online 3 2 2004 URL: http://www.currentpsychiatry.com/2004.02/0204_out_of_thepipeline.asp
20. Brock G Nehra A Lipshultz LI et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy J Urol 170 2003 1278-1283
21. Montorsi F McDermott TE Morgan R et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies Urology 53 1999 1011-1018
22. Goldstein I Young JM Fischer J Bangerter K Segerson T Taylor T Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study Diabetes Care 26 2003 777-783
23. Rendell MS Rajfer J Wicker PA Smith MD Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized control trial. Sildenafil Diabetes Study Group JAMA 281 1999 421-426
24. Boulton AJ Selam JL Sweeney M Ziegler D Sildenafil citrate for the teratment of erectile dysfunction in men with Type II diabetes mellitus Diabetologia 44 2001 1296-1301
25. Thadani U Smith W Nash S et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease J Am Coll Cardiol 40 2002 2006-2012
26. Morganroth J Ilson BE Shaddinger BC et al. Evaluation of vardenafil and sildenafil on cardiac repolarization Am J Cardiol 93 2004 1378-1383 A6
27. Aversa A Mazzilli F Rossi T Delfino M Isidori AM Fabbri A Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males Hum Reprod 15 2000 131-134
28. Paniagua FA Commentary on the possibility that Viagra may contribute to transmission of HIV and other sexual diseases among older adults Psychol Rep 85 1999 942-944
29. Cachay E Mar-Tang M Mathews WC Screening for potentially transmitting sexual risk behaviors, urethral sexually transmitted infection, and sildenafil use among males entering care for HIV infection AIDS Patient Care STDS 18 2004 349-354
30. Romanelli F Smith KM Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males Ann Pharmacother 38 2004 1024-1030